AGIOS PHARMACEUTICALS (AGIO) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
AGIOS PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $4.8M of AGIO stock on the open market.
Get emailed when insiders cluster-buy stocks like AGIO
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AGIO insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $1.1M | 2 |
| Q2 2026 | — | 0 | $1.2M | 7 |
| Q1 2026 | — | 0 | $1.4M | 22 |
| Q4 2025 | — | 0 | $1.1M | 11 |
| Q3 2025 | — | 0 | $8K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 AGIOS PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $4.8M. 42 of 43 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
AGIO earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Jul 30, 2026 | -12.3% | Sold $151K | -14.3%S&P +2.4% | +11.0% |
| Apr 29, 2026 | -25.2% | Sold $1.2M | +12.9%S&P +1.0% | +5.0% |
| Feb 12, 2026 | -3.3% | None | +0.9%S&P -1.5% | -0.4% |
| Oct 30, 2025 | +4.3% | Sold $161K | +3.1%S&P -0.8% | -32.5% |
| Jul 31, 2025 | -4.2% | None | -6.8%S&P -2.0% | +7.7% |
| May 1, 2025 | +6.7% | None | +1.4%S&P +2.2% | +6.6% |
| Feb 13, 2025 | -2.2% | None | +1.2%S&P +1.1% | -6.9% |
| Oct 31, 2024 | +10.1% | None | -3.1%S&P -1.5% | +32.4% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 6SEC | Sarah GheuensChief Medical Officer | Sell Plan | 30,00054,645 held (−35%) | $30.48 | $914K | +4.4% | — |
| Jul 2SEC | Sarah GheuensChief Medical Officer | Sell Plan | 4,00784,645 held (−5%) | $37.56 | $151K | -15.3% | — |
| Apr 6SEC | Brian GoffCEO | Sell Plan | 12,472177,604 held (−7%) | $34.71 | $433K | -8.4% | — |
| Apr 6SEC | Brian GoffCEO | Sell Plan | 6,596184,508 held (−3%) | $34.71 | $229K | -8.4% | — |
| Apr 6SEC | James William BurnsGeneral Counsel | Sell Plan | 3,28049,306 held (−6%) | $34.71 | $114K | -8.4% | — |
| Apr 6SEC | Tsveta MilanovaChief Commercial Officer | Sell Plan | 3,26246,829 held (−7%) | $34.71 | $113K | -8.4% | — |
| Apr 6SEC | Cecilia JonesCFO | Sell Plan | 3,14154,998 held (−5%) | $34.71 | $109K | -8.4% | — |
| Apr 6SEC | Krishnan ViswanadhanChief Corp Dev & Strategy | Sell Plan | 2,95910,282 held (−22%) | $34.71 | $103K | -8.4% | — |
| Apr 6SEC | Sarah GheuensChief Medical Officer | Sell Plan | 2,94080,277 held (−4%) | $34.71 | $102K | -8.4% | — |
| Mar 9SEC | Krishnan ViswanadhanChief Corp Dev & Strategy | Sell Plan | 2,9595,141 held (−37%) | $27.80 | $82K | +14.4% | — |
| Mar 5SEC | Theodore James Washburn Jr.Principal Accounting Officer | Sell | 5,272868 held (−86%) | $28.88 | $152K | +10.1% | — |
| Mar 3SEC | Brian GoffCEO | Sell Plan | 8,267157,466 held (−5%) | $28.96 | $239K | +9.8% | — |
| Mar 3SEC | Brian GoffCEO | Sell Plan | 5,918164,548 held (−3%) | $28.96 | $171K | +9.8% | — |
| Mar 3SEC | Brian GoffCEO | Sell Plan | 3,870147,733 held (−3%) | $28.96 | $112K | +9.8% | — |
| Mar 3SEC | Sarah GheuensChief Medical Officer | Sell Plan | 1,68171,593 held (−2%) | $28.96 | $49K | +9.8% | — |
| Mar 3SEC | Cecilia JonesCFO | Sell Plan | 1,68142,785 held (−4%) | $28.96 | $49K | +9.8% | — |
| Mar 3SEC | James William BurnsGeneral Counsel | Sell Plan | 1,68138,516 held (−4%) | $28.96 | $49K | +9.8% | — |
| Mar 3SEC | Tsveta MilanovaChief Commercial Officer | Sell Plan | 1,68138,778 held (−4%) | $28.96 | $49K | +9.8% | — |
| Mar 3SEC | Cecilia JonesCFO | Sell Plan | 1,57349,328 held (−3%) | $28.96 | $46K | +9.8% | — |
| Mar 3SEC | Sarah GheuensChief Medical Officer | Sell Plan | 1,18767,608 held (−2%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | Sarah GheuensChief Medical Officer | Sell Plan | 1,18774,406 held (−2%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | Cecilia JonesCFO | Sell Plan | 1,18745,598 held (−3%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | James William BurnsGeneral Counsel | Sell Plan | 1,18734,531 held (−3%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | James William BurnsGeneral Counsel | Sell Plan | 1,18741,329 held (−3%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | Tsveta MilanovaChief Commercial Officer | Sell Plan | 1,18741,591 held (−3%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | James William BurnsGeneral Counsel | Sell Plan | 1,16344,086 held (−3%) | $28.96 | $34K | +9.8% | — |
| Mar 3SEC | Theodore James Washburn Jr.Principal Accounting Officer | Sell Plan | 7986,140 held (−12%) | $28.96 | $23K | +9.8% | — |
| Mar 3SEC | Theodore James Washburn Jr.Principal Accounting Officer | Sell Plan | 7274,243 held (−15%) | $28.96 | $21K | +9.8% | — |
| Mar 3SEC | Theodore James Washburn Jr.Principal Accounting Officer | Sell Plan | 6982,595 held (−21%) | $28.96 | $20K | +9.8% | — |
| Mar 3SEC | Cecilia JonesCFO | Sell Plan | 59438,800 held (−2%) | $28.96 | $17K | +9.8% | — |
| Jan 7SEC | Tsveta MilanovaChief Commercial Officer | Sell Plan | 2,87234,793 held (−8%) | $27.02 | $78K | +17.7% | — |
| Jan 2SEC | Brian GoffCEO | Sell Plan | 12,473136,583 held (−8%) | $27.09 | $338K | +17.4% | — |
| Jan 2SEC | Brian GoffCEO | Sell Plan | 6,230143,103 held (−4%) | $27.09 | $169K | +17.4% | — |
| Jan 2SEC | Tsveta MilanovaChief Commercial Officer | Sell Plan | 2,93229,190 held (−9%) | $27.09 | $79K | +17.4% | — |
| Jan 2SEC | Sarah GheuensChief Medical Officer | Sell Plan | 2,93264,795 held (−4%) | $27.09 | $79K | +17.4% | — |
| Jan 2SEC | Cecilia JonesCFO | Sell Plan | 2,93237,394 held (−7%) | $27.09 | $79K | +17.4% | — |
| Jan 2SEC | James William BurnsGeneral Counsel | Sell Plan | 2,93231,718 held (−8%) | $27.09 | $79K | +17.4% | — |
| Nov 14SEC | David ScaddenDirector | Sell Plan | 20017,603 held (−1%) | $43.84 | $9K | -27.4% | — |
| Nov 13SEC | Sarah GheuensChief Medical Officer | Sell Plan | 2,45461,727 held (−4%) | $43.78 | $107K | -27.3% | — |
| Nov 3SEC | Sarah GheuensChief Medical Officer | Sell Plan | 20061,727 held (−0%) | $43.81 | $9K | -27.4% | — |
| Oct 29SEC | Sarah GheuensChief Medical Officer | Sell Plan | 3,30261,727 held (−5%) | $43.92 | $145K | -27.6% | — |
| Oct 10SEC | David ScaddenDirector | Sell Plan | 20017,603 held (−1%) | $41.00 | $8K | -22.4% | — |
| Oct 2SEC | David ScaddenDirector | Sell Plan | 20017,603 held (−1%) | $40.00 | $8K | -20.5% | — |
Insiders at AGIOS PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Brian GoffCEO | — | $1.7M | Apr 6, 2026 | — |
| Sarah GheuensChief Medical Officer | — | $1.6M | Aug 6, 2026 | — |
| Tsveta MilanovaChief Commercial Officer | — | $353K | Apr 6, 2026 | — |
| James William BurnsGeneral Counsel | — | $344K | Apr 6, 2026 | — |
| Cecilia JonesCFO | — | $334K | Apr 6, 2026 | — |
| Theodore James Washburn Jr.Principal Accounting Officer | — | $217K | Mar 5, 2026 | — |
| Krishnan ViswanadhanChief Corp Dev & Strategy | — | $185K | Apr 6, 2026 | — |
| David ScaddenDirector | — | $25K | Nov 14, 2025 | — |
AGIO stock: common questions
Are AGIOS PHARMACEUTICALS, INC. insiders buying AGIO stock?
In the past 12 months, 0 insiders reported open-market purchases of AGIO worth $0.
Are AGIOS PHARMACEUTICALS, INC. insiders selling AGIO stock?
8 insiders reported sales worth $4.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AGIO's 52-week range?
Over the past year AGIO has traded between $22.34 and $45.49. It last closed at $31.81 on Oct 9, 2026.